VISION-DMD is a patient group, industry and academic researcher driven Horizon 2020 project. Venture philanthropy through patient group funding and public investment has been critical to advance the clinical development of vamorolone, an innovative drug for the treatment of Duchenne Muscular Dystrophy (DMD). The project hopes to be a model for affordable rare disease drug development while aiming to advance and accelerate the clinical development through late stage clinical trials being conducted in Europe, the US, Canada, Israel and Australia. This project has received funding from the European Union’s Horizon 2020 research and innovation programme  under grant agreement No 667078.